LogicBio Therapeutics to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Feb. 26, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that chief executive officer Frederic Chereau will be presenting an overview of the company at upcoming investor conferences.
Mr. Chereau will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 4:10 p.m. ET. A link to the Barclays presentation will be available under the "Events and Presentations" section of LogicBio's website, found here: https://investor.logicbio.com/events-and-presentations/events.
Mr. Chereau will also record a presentation for the H.C. Wainwright Global Life Sciences Conference, which will be available on the H.C Wainwright website for the duration of the conference, March 9-10, 2021.
About LogicBio Therapeutics, Inc.
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRideTM platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVyTM capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit https://www.logicbio.com/.
Media Contacts:
Adam Daley Berry & Company Public Relations W: 212-253-8881 C: 614-580-2048 [email protected]
Jenna Urban Berry & Company Public Relations W: 212-253-8881 C: 203-218-9180 [email protected]
Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2024 financial results and highlighted recent corporate updates....
The judgment in Bennett, et. al v. Providence Health & Services, was entered in King County Superior Court yesterday, the culmination of a two-week trial which took place late last month. Providence is ordered to pay more than 33,000 of its hourly...
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and...
Dentalcorp Holdings Ltd. ("Dentalcorp" or the "Company") , Canada's largest and one of North America's fastest growing networks of dental practices, today announced its financial and operating results for the first quarter ended March 31, 2024. All...
Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the "Best Overall Mental Health Solution" award in the eighth annual MedTech...
REGENXBIO Inc. today announced it will participate in the following upcoming investor conferences:
BofA Securities Health Care Conference 2024Fireside Chat: Wednesday, May 15, 2024 at 2:20 p.m. ETLocation: Las Vegas, NV
Stifel 2024 Tailoring Genes...